SNGX: צמיחת רווחי EPS רבעונית Soligenix
The quarterly EPS change demonstrates volatility due to reliance on component supplies from Asia and logistical risks, with the latest value recorded as 90.80. Soligenix, Inc. revenues are based on government contracts for biodefense and lymphoma treatment. The development strategy relies on the independent promotion of drugs and securing grants without pursuing external acquisitions to preserve capital.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_SNGX_-_Soligenix-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Soligenix (SNGX): צמיחת רווחי EPS רבעונית מ-04.07.2022 עד 12.11.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור Soligenix, Inc. (SNGX)
When screening assets, an investor assesses business resilience through net income per share dynamics, which measure capital generation efficiency relative to the volume of issuance. For Soligenix, Inc. (SNGX), this metric reflects the monetization of government contracts and niche drugs, allowing for the verification of the fundamental growth trend through the comparison of quarterly EPS regardless of price wars.
